166.44 +0.99 (0.60%)
After hours: 7:36PM EDT
|Bid||165.56 x 800|
|Ask||166.45 x 1300|
|Day's range||163.93 - 166.40|
|52-week range||121.50 - 176.64|
|Beta (5Y monthly)||0.62|
|PE ratio (TTM)||48.38|
|Earnings date||06 May 2021|
|Forward dividend & yield||1.00 (0.61%)|
|Ex-dividend date||20 Apr 2021|
|1y target est||186.67|
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.
Heska has benefited from fast growth in the veterinary market, but should investors keep betting on the stock?